TRVITrevi Therapeutics, Inc. Common Stock US Stock
Open: $2.23 High: $2.24 Low: $2.01 Close: $2.01
Range: 2022-06-27 - 2022-06-28Volume:124,017
Powered by Finage Stock APIDelayed data
Trevi Therapeutics, Inc. Common Stock 195 CHURCH STREET https://www.trevitherapeutics.comTrevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
- Employees: 23